Hausstaubmilbe (D. Pteronyssinus) Bencard Allergie

Hausstaubmilbe (D. Pteronyssinus) Bencard Allergie is an allergen extract containing Dermatophagoides pteronyssinus, supplied as an intra‑epidermal preparation for diagnostic and therapeutic use. The product is manufactured for the EU market and is available by prescription only. It provides a reliable standardized concentration of house‑dust‑mite allergen to support skin testing and allergen‑specific immunotherapy, facilitating accurate diagnosis and potential medical desensitization in patients with clinically confirmed sensitivity.

Hausstaubmilbe (D. Pteronyssinus) Bencard Allergie is indicated for specific clinical situations related to house‑dust‑mite allergy.

- Diagnosis of IgE‑mediated allergy to Dermatophagoides pteronyssinus via skin prick testing. - Allergen‑specific immunotherapy for patients with confirmed house dust mite allergy. - Adjunct to environmental control measures in comprehensive allergy management. - Use in specialized allergy clinics under physician supervision. - Potential inclusion in approved research protocols involving allergen extracts.

Adverse reactions to Hausstaubmilbe (D. Pteronyssinus) Bencard Allergie are generally mild but may include more serious events.

Common: - Local redness at the injection site. - Swelling or wheal formation. - Itching or mild pruritus. - Transient urticaria. - Mild headache. - Temporary dizziness.

Serious: - Systemic anaphylaxis. - Severe bronchospasm or asthma exacerbation. - Angioedema of the face or throat. - Hypotension or shock. - Prolonged urticaria lasting more than 24 hours. - Serum‑sickness‑like reaction.

Before prescribing Hausstaubmilbe (D. Pteronyssinus) Bencard Allergie, clinicians should consider several precautionary measures.

- Confirm IgE‑mediated sensitivity before initiating immunotherapy. - Avoid use in patients with uncontrolled asthma. - Do not use in pregnant or lactating women unless the benefit clearly outweighs potential risk. - Observe the patient for at least 30 minutes after administration for early signs of systemic reaction. - Ensure emergency equipment and medications for anaphylaxis are readily available. - Store the product according to the manufacturer’s temperature and handling instructions. - Discontinue treatment if a severe adverse reaction occurs.

Certain medications and substances may modify the safety or efficacy of Hausstaubmilbe (D. Pteronyssinus) Bencard Allergie.

Avoid: - Beta‑blockers, which can worsen anaphylactic outcomes. - ACE inhibitors, due to potential angioedema risk. - High‑dose systemic corticosteroids that may suppress the immunologic response. - Antihistamines taken shortly before skin testing, as they can reduce wheal size. - Immunosuppressants that blunt the intended immunotherapy effect.

Use with caution: - NSAIDs, which may increase the likelihood of systemic reactions. - IgE‑targeting monoclonal antibodies (e.g., omalizumab). - Concurrent administration of other allergen extracts. - Vaccinations given within a short interval of allergen exposure. - Alcohol consumption, which can potentiate vasodilatory effects.